An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer

BACKGROUND: There is no clear standard of care for advanced/recurrent endometrial cancer (EC) following platinum-based therapy. Dostarlimab is approved for patients with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) advanced/recurrent EC. This indirect treatment comparison...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathews, Cara, Lorusso, Domenica, Coleman, Robert L, Boklage, Susan, Garside, Jamie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Gynecologic Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732237/
https://www.ncbi.nlm.nih.gov/pubmed/36124638
http://dx.doi.org/10.1093/oncolo/oyac188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732237/
https://www.ncbi.nlm.nih.gov/pubmed/36124638
http://dx.doi.org/10.1093/oncolo/oyac188

Ejemplares similares